The AHA's Committee on Behavioral Health today announced its chair, chair-elect and new members for 2025. The officers are:

  • Zelia Baugh, executive vice president, behavioral health, JPS Health Network,  committee chair. 
  • Mary Marran, president and COO, Butler Hospital and chief administrative officer, Care New England, chair-elect. 
  • Jill Howard, R.N., senior consultant, Sheppard Pratt Solutions, past chair. 

 
Joining the committee as new members are:

  • Paul Rains, R.N., president, St. Joseph’s Behavioral Health Center and system senior vice president of behavioral health, Common Spirit. 
  • Scott Nygaard, M.D., former chief operating officer, Lee Health. 
  • Marlene Martin, M.D., director, addiction care team, University of California San Francisco Medical center; director, addiction initiatives, UCSF Latinx Center of Excellence; and associate professor of clinical medicine, UCSF.   

 
Reappointed to another three-year term is:

  • Amanda Klahr, R.N., nursing director, inpatient behavioral health services, Denver Health 


The committee advises AHA on policy and advocacy and provides a forum for strategic discussion of issues important to behavioral health providers and the field. Learn more about AHA’s work on behavioral health

Related News Articles

Headline
A new initiative launched March 18 by the Dr. Lorna Breen Heroes' Foundation seeks to improve mental health care access for health care workers. The program,…
Headline
A study published Feb. 26 by JAMA Psychiatry found that female physicians died by suicide at more than 1.5 times the rate of female nonphysicians from 2017-…
Headline
The Dr. Lorna Breen Heroes’ Foundation Feb. 26 recognized 43 licensure boards and 521 hospitals for changing invasive and stigmatizing mental health questions…
Headline
The AHA voiced support for bipartisan House legislation introduced Feb. 4 to reauthorize for five years the Dr. Lorna Breen Health Care Provider Protection Act…
Headline
In this new “Caring for Our Kids” episode, David Wagner, pediatric psychologist at Oregon Health and Science University, discusses the Novel Interventions in…
Headline
The Food and Drug Administration Jan. 30 announced it approved Journavx (suzetrigine) oral tablets, a first-in-class non-opioid drug, to treat moderate to…